PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

(2021) Guoxing Zhao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

(2021) Zhiyong Wang et al.   Nature Communications

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells

(2020) Connor J. Dwyer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells

(2020) Patryk Górniak et al.   Molecular Oncology

Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes

(2020) Rebecca S. Hesterberg et al.   BLOOD

Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy

(2020) Carly Bess Williams et al.   BREAST CANCER RESEARCH AND TREATMENT

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

(2020) Gaia Giannone et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

(2020) Ilaria Proietti et al.   Cancers

Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity

(2020) Pu Sun et al.   ACTA PHARMACOLOGICA SINICA

Upcoming market catalysts in Q1 2021

(2020) Kaniaw Dilzer   NATURE REVIEWS DRUG DISCOVERY

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

(2019) Alain Patrick Algazi et al.   Pigment Cell & Melanoma Research

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas

(2019) Filippo Spriano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers

(2019) Andrew R. Haas et al.   MOLECULAR THERAPY

T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia

(2019) Simo Xia et al.   Cellular & Molecular Immunology

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

(2019) Dan A. Erkes et al.   Cancer Discovery

The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations

(2018) Dearbhaile C. Collins et al.   CURRENT CANCER DRUG TARGETS

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications

(2018) Ulrike Köhl et al.   HUMAN GENE THERAPY

PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells

(2018) Wenting Zheng et al.   LEUKEMIA

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

(2018) Jake S. O’Donnell et al.   SEMINARS IN CANCER BIOLOGY

T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response

(2018) Laura Aragoneses-Fenoll et al.   Frontiers in Immunology

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

(2018) Concetta Quintarelli et al.   OncoImmunology

Programming CAR-T cells to kill cancer

(2018) Louai Labanieh et al.   Nature Biomedical Engineering

Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation

(2018) Seiichi Okabe et al.   ANNALS OF HEMATOLOGY

Duvelisib: First Global Approval

(2018) Hannah A. Blair   DRUGS

Modulation of PI3K signaling to improve CAR T cell function

(2018) Wenting Zheng et al.   Oncotarget

Engineering CAR-T Cells for Improved Function Against Solid Tumors

(2018) Michael A. Morgan et al.   Frontiers in Immunology

Ibrutinib treatment improves T cell number and function in CLL patients

(2017) Meixiao Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

(2017) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

(2017) Julia Tchou et al.   Cancer Immunology Research

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

(2017) Kristen M. Hege et al.   Journal for ImmunoTherapy of Cancer

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

(2017) Ryan Urak et al.   Journal for ImmunoTherapy of Cancer

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

(2016) Patricia Mucci LoRusso   JOURNAL OF CLINICAL ONCOLOGY

Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

(2016) Zhen Jin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation

(2016) Mario Mandalà et al.   LABORATORY INVESTIGATION

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

(2016) Fengtao You et al.   Science China-Life Sciences

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

(2016) Nathan Singh et al.   Science Translational Medicine

A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies

(2016) Tangying Lily Lu et al.   Human Gene Therapy Methods

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy

(2015) Christopher A. Klebanoff et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

(2015) Guang Yang et al.   Oncotarget

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+T-cell proliferation and survival

(2015) Rasha Abu Eid et al.   OncoImmunology

Adoptive Immunotherapy for Cancer or Viruses

(2014) Marcela V. Maus et al.   Annual Review of Immunology

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus

(2014) Sarah J. Fleischer et al.   Arthritis & Rheumatology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

(2013) Minmin Song et al.   PLoS One

Role of PI3K/Akt signaling in memory CD8 T cell differentiation

(2013) Eui Ho Kim et al.   Frontiers in Immunology

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

(2012) Kimberly Noonan et al.   CLINICAL CANCER RESEARCH

Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation

(2012) E. H. Kim et al.   JOURNAL OF IMMUNOLOGY

Sorting Through Subsets

(2012) Christopher A. Klebanoff et al.   JOURNAL OF IMMUNOTHERAPY

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Does the PI3K pathway promote or antagonize regulatory T cell development and function?

(2012) Dalya R. Soond et al.   Frontiers in Immunology

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism

(2011) Andrew N. Macintyre et al.   IMMUNITY

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE